Global Anti-Obesity Drugs Market to Reach US$10.3 Billion by 2017, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Anti-Obesity Drugs market. The global market for Anti-Obesity Drugs is projected to reach US$10.3 billion by the year 2017, driven by increasing prevalence of obesity and introduction of novel drugs, currently in pipeline. Additionally, shift in perception of obesity as a health disorder or disease rather than lifestyle condition is slated to accelerate growth momentum over the long term.

Anti-Obesity Drugs: A Global Strategic Business Report

Follow us on LinkedIn – The global anti-obesity drugs market is characterized by the availability of few effective drugs of which only limited drugs have been approved for long-term use. The rising obesity prevalence offers enhanced opportunities to drug manufacturing companies to offer new and highly effective drugs. The indirect and direct costs associated with obesity and its related conditions are considerably high and the increasing prevalence and socioeconomic costs of obesity are compelling governments across the world to introduce anti-obesity initiatives.

Further, drug metabolism is fast emerging as a new subject of concern. Dose of a drug is evaluated on the basis of its weight, while dosage information found on labels of OTC drugs is addressed according to the age of a patient. Majority of the presently available drugs do not meet the requirements for safety profile and efficacy. Several anti-obesity drugs have been approved for short term usage owing to the high risk of adverse efforts associated with their usage. The reported side-effects of various anti-obesity drugs have compelled European and the US regulatory authorities to withdraw or ban a number of anti-obesity drugs. Further, drug approval agencies in the US and Europe have been reluctant to approve new anti-obesity drugs. Since 1930s, sales of several anti-obesity drugs such as amphetamine, dinitrophenol, amniotes, thyroid hormone, phenylpropanolamine and fenfluramine were suspended due to side-effects, particularly on pulmonary and cardiovascular systems.

As stated by the new market research report on Anti-Obesity Drugs, the US continues to remain the largest and the fastest growing regional market. The US is home to the majority of world’s obese population and the number is still on the rise. Therapies for obesity and associated diseases account for a substantial chunk of the overall healthcare expenditure in the US. Given the increasing prevalence of obesity in the US and other parts of the world, and the lack of any blockbuster drug, the market offers immense potential for effective anti-obesity drugs with lower side-effect profile. Europe represents one of the leading markets for anti-obesity drugs. Despite the rise in number of obese patients, the pace of growth has been relatively slow primarily due to the lack of reimbursement. Asia-Pacific holds enormous potential for anti-obesity drugs. Rising consumer affluence, increased consumption of high calorie fast foods, and sedentary lifestyles are contributing to an increase in the obese population, thereby offering opportunities for drug makers.

Competition in the anti-obesity drugs market is expected to intensify with new drugs likely to hit the market in near term. The landscape is vast with contenders including biotech companies such as Arena Pharmaceuticals and Orexigen Therapeutics to giant pharmaceutical companies gearing up to develop safer anti-obesity drugs with lower side effects. Although there is no guarantee that the new drugs would not cause any side effects, introduction of the drugs in the market would provide more choice to physicians and aid them in prescribing appropriate medication for obese patients. Xenical is currently the top selling brand in the global anti-obesity drugs market. Removal of high-revenue generating drugs from the market intensely affected the anti-obesity drug market in 2009 and 2010. Acomplia (Rimonabant) from Sanofi-Aventis was taken off from the European market in 2008 following reports of psychiatric disorders in patients. The ban on Acomplia led to more aggressive competition between Xenical and Reductil, the leading obesity drugs in 2009. Major players profiled in the report include Arena Pharmaceuticals, AstraZeneca Plc, Roche, GlaxoSmithKline, Orexigen Therapeutics, VIVUS, among others.

The research report titled “Anti-Obesity Drugs: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections in US$ Million across geographic markets such as the US, Europe (France, Germany, Italy, UK, and Rest of Europe), and Rest of World.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website